Liraglutide: Dosage, Protocol, and Research Guide
GLP-1 receptor agonist for weight management and type 2 diabetes control
Mechanism
97% homologous to human GLP-1, with modifications for extended half-life. Increases insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through hypothalamic pathways.
Protocol at a glance
| Starting dose | 0.6mg |
|---|---|
| Maintenance dose | 1.2-3.0mg |
| Maximum dose | 3.0mg |
| Frequency | Once daily |
| Typical duration | Ongoing therapy |
| Route | Subcutaneous |
| Injection site | Abdomen, thigh, or upper arm |
| Timing | Any time of day, with or without food |
Titration schedule
| Week | Dose | Notes |
|---|---|---|
| 1 | 0.6mg | Initial dose for 1 week |
| 2 | 1.2mg | Standard maintenance dose |
| 3 | 1.8mg | If additional effect needed |
| 4 | 3.0mg | Maximum dose for weight loss |
Side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Hypoglycemia
Contraindications
- Type 1 diabetes
- History of pancreatitis
- Gastroparesis
- MEN 2 syndrome
Protocol notes
- Take at same time each day
- Rotate injection sites
- Monitor for hypoglycemia if on other diabetes medications
- Saxenda brand for weight loss, Victoza for diabetes
Frequently asked questions
What is Liraglutide and how does it work?
Liraglutide is a GLP-1 receptor agonist that is 97% homologous to human glucagon-like peptide-1, a hormone critical to glucose regulation and appetite control. Liraglutide includes chemical modifications that extend its half-life, enabling once-daily dosing. It works through multiple mechanisms: increasing insulin secretion in response to high blood glucose, suppressing glucagon release, delaying gastric emptying to promote fullness, and reducing appetite through hypothalamic pathways. This multi-target approach makes it effective for both weight management and glucose control.
What is the standard dosing protocol for Liraglutide?
Liraglutide therapy begins at 0.6mg once daily and is titrated to a maintenance dose of 1.2–3.0mg once daily, with a maximum dose of 3.0mg daily. It is administered via subcutaneous injection to the abdomen, thigh, or upper arm. Liraglutide can be injected at any time of day with or without food, though consistent timing is recommended. Injection sites should be rotated to minimize local tissue complications.
What are the common side effects of Liraglutide?
Common side effects include nausea, vomiting, diarrhea, and headache, with gastrointestinal effects often diminishing over time as the body adjusts. Hypoglycemia is a concern, particularly if Liraglutide is used with other diabetes medications—patients in this situation should monitor blood glucose regularly. Individual responses vary; some experience significant side effects while others tolerate the medication well.
Who should not use Liraglutide?
Liraglutide is contraindicated in type 1 diabetes, personal or family history of medullary thyroid carcinoma (MEN 2 syndrome), prior pancreatitis, and gastroparesis. These contraindications reflect Liraglutide's mechanism of action and the potential for adverse outcomes in specific populations. Medical evaluation is essential before use to determine individual suitability.
Can Liraglutide be cycled or stacked with other peptides?
Research on Liraglutide cycling and stacking remains limited. Combining Liraglutide with other medications—especially diabetes agents—requires careful medical supervision due to hypoglycemia risk. The safety and efficacy of such combinations have not been systematically established in available literature. Any consideration of cycling or combining Liraglutide must be discussed with a licensed healthcare provider.
What lab markers should be monitored while using Liraglutide?
Blood glucose monitoring is essential, particularly for those taking concurrent diabetes medications. Baseline and periodic assessment of kidney function and pancreatic enzymes may be prudent given the contraindication history of pancreatitis. Regular medical follow-up allows for dose adjustments and early detection of any adverse effects.
Is Liraglutide legal or FDA-approved for human use?
For research purposes only — Liraglutide is not FDA-approved for human use outside its designated medical indications (Saxenda for weight loss, Victoza for type 2 diabetes) when prescribed by a licensed physician. Legal status and regulatory approval vary by jurisdiction. Consult a licensed physician to understand the regulatory landscape in your region.
What is the difference between Saxenda and Victoza Liraglutide formulations?
Saxenda and Victoza are both brand names for the same active ingredient, Liraglutide, but differ in their indicated use. Saxenda is formulated and marketed for weight management, while Victoza is approved for type 2 diabetes control. Both contain identical Liraglutide and operate through the same GLP-1 mechanism. The choice depends on the clinical indication and is determined by a healthcare provider.
More GLP-1 & Weight Loss peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.